Jump to Main Content
Controlling release from 3D printed medical devices using CLIP and drug-loaded liquid resins
- Bloomquist, Cameron J., Mecham, Michael B., Paradzinsky, Mark D., Janusziewicz, Rima, Warner, Samuel B., Luft, J. Christopher, Mecham, Sue J., Wang, Andrew Z., DeSimone, Joseph M.
- Journal of controlled release 2018 v.278 pp. 9-23
- biocompatibility, drugs, encapsulation, geometry, image analysis, ingredients, liquids, manufacturing, medical equipment, medicine, models, polyethylene glycol, resins
- Mass customization along with the ability to generate designs using medical imaging data makes 3D printing an attractive method for the fabrication of patient-tailored drug and medical devices. Herein we describe the application of Continuous Liquid Interface Production (CLIP) as a method to fabricate biocompatible and drug-loaded devices with controlled release properties, using liquid resins containing active pharmaceutical ingredients (API). In this work, we characterize how the release kinetics of a model small molecule, rhodamine B-base (RhB), are affected by device geometry, network crosslink density, and the polymer composition of polycaprolactone- and poly (ethylene glycol)-based networks. To demonstrate the applicability of using API-loaded liquid resins with CLIP, the UV stability was evaluated for a panel of clinically-relevant small molecule drugs. Finally, select formulations were tested for biocompatibility, degradation and encapsulation of docetaxel (DTXL) and dexamethasone-acetate (DexAc). Formulations were shown to be biocompatible over the course of 175 days of in vitro degradation and the clinically-relevant drugs could be encapsulated and released in a controlled fashion. This study reveals the potential of the CLIP manufacturing platform to serve as a method for the fabrication of patient-specific medical and drug-delivery devices for personalized medicine.